Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer

NCT06782932 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: AGEN2373
DRUG: Balstilimab
DRUG: Cyclophosphamide
DRUG: GVAX
DRUG: AGEN2373 (RP2D)
DRUG: Balstilimab
DRUG: mKRASvax

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]
[object Object]
[object Object]